Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (3): 470-478. doi: 10.19723/j.issn.1671-167X.2020.03.012

Previous Articles     Next Articles

Relationship between serum vitamin E concentration in first trimester and the risk of developing hypertension disorders complicating pregnancy

Wen-ying MENG1,Wan-tong HUANG2,Jie ZHANG2,Ming-yuan JIAO3,Lei JIN4,Lei JIN2,△()   

  1. 1. Department of Obstetrics, Tongzhou Maternal & Child Health Hospital of Beijing, Beijing 101100, China
    2. Institute of Reproductive and Child Health, National Health Commission Key Laboratory of Reproductive Health, Peking University, Beijing 100191, China; Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
    3. Department of Clinical Laboratory, Tongzhou Maternal & Child Health Hospital of Beijing, Beijing 101100, China
    4. Department of Maternal Health Care, Tongzhou Maternal & Child Health Hospital of Beijing, Beijing 101100, China
  • Received:2020-02-16 Online:2020-06-18 Published:2020-06-30
  • Contact: Lei JIN E-mail:songyi@bjmu.edu.cn
  • Supported by:
    National Key R&D Program of China(2018YFC1004301)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate the incidence of hypertension disorders complicating pregnancy (HDCP) and vitamin E (VE) nutritional status among pregnant women in Beijing, and to determine the relationship between serum VE concentration in the first trimester of pregnancy and the risk of developing HDCP.Methods: A retrospective cohort study was performed including 22 283 cases of pregnant women who underwent singleton deliveries in Tongzhou Maternal & Child Health Hospital of Beijing from January 2016 through December 2018 and received tests of serum VE concentrations in the first trimester of pregnancy. Nonconditional Logistic regression model was used to analyze the association between serum VE concentration levels and the risk of developing HDCP.Results: The total incidence of HDCP was 5.4%, with the incidence of gestational hypertension around 2.1% and the incidence of preeclampsia-eclampsia around 3.3%. The median concentration of serum VE in early pregnancy was 10.1 (8.8-11.6) mg/L, and 99.7% of the participants had normal serum VE concentrations. The incidence of gestational hypertension and that of preeclampsia-eclampsia had been annually increasing in three years; a linear-by-linear association had also been observed between the serum VE concentrations and the years of delivery. According to the results of the univariable and the multivariable Logistic regression analyses, higher risks of developing HDCP had been observed among women with higher serum VE concentrations. Compared to those with serum VE concentrations in interquartile range (P25-P75) of all the participants, the women whose serum VE concentrations above P75 were at higher risks to be attacked by HDCP (OR = 1.34, P < 0.001), gestational hypertension (OR = 1.39, P = 0.002), or preeclampsia-eclampsia (OR = 1.34, P = 0.001), as suggested by the results of the multivariable Logistic regression model analyses. In addition, the women with serum VE concentrations of 11.2 mg/L or above had a significantly higher risk of developing HDCP than those whose serum VE concentrations of P40-P60 of all the participants, and this risk grew higher as serum VE concentrations in the first trimester of pregnancy increased.Conclusion: Women in Beijing are at good nutritional status. From January 2016 to December 2018, the incidence of HDCP increased with serum VE concentration level, and serum VE concentration of 11.2 mg/L is an indicator of an increased risk of developing HDCP, suggesting that pregnant women should take nutritional supplements containing VE carefully.

Key words: Hypertension, Eclampsia, Pregnancy, Vitamin E, Cohort study

CLC Number: 

  • R172

Figure 1

Flow diagram of study sample selection"

Table 1

General characteristics of the participants by their vitamin E nutritional status"

Characteristics Total number
(n = 22 283),
n (%)		 VE normala
(n = 22 206),
n (%)		 VE deficienta
(n = 13),
n (%)		 VE excessivea
(n = 64),
n (%)		 P
Delivery year
2016 7 216 (32.4) 7 194 (32.4) 10 (76.9) 12 (18.8) 0.001b
2017 7 677 (34.5) 7 653 (34.5) 1 (7.7) 23 (35.9)
2018 7 390 (33.2) 7 359 (33.1) 2 (15.4) 29 (45.3)
Maternal age/years
17 - 1 996 (9.0) 1 988 (9.0) 4 (30.8) 4 (6.3) 0.001b
25 - 10 501 (47.1) 10 476 (47.2) 6 (46.2) 19 (29.7)
30 - 7 313 (32.8) 7 287 (32.8) 2 (15.4) 24 (37.5)
35 - 51 2 473 (11.1) 2 455 (11.1) 1 (7.7) 17 (26.6)
Ethnic
Han 20 959 (94.1) 20 885 (94.1) 12 (92.3) 62 (96.9) 0.523b
Others 1 324 (5.9) 1 321 (5.9) 1 (7.7) 2 (3.1)
Education level
Middle school or lower 1 905 (8.5) 1 902 (8.6) 2 (15.4) 1 (1.6) 0.080b
High school or secondary technical school 4 219 (18.9) 4 199 (18.9) 4 (30.8) 16 (25.0)
College 7 168 (32.2) 7 140 (32.2) 5 (38.5) 23 (35.9)
University or above 8 991 (40.3) 8 965 (40.4) 2 (15.4) 24 (37.5)
Pre-pregnant BMI
Normal 14 079 (63.2) 14 046 (63.3) 9 (69.2) 24 (37.5) <0.001b
Underweight 2 340 (10.5) 2 334 (10.5) 2 (15.4) 4 (6.3)
Overweight 4 501 (20.2) 4 473 (20.1) 2 (15.4) 26 (40.6)
Obesity 1 363 (6.1) 1 353 (6.1) 0 (0.0) 10 (15.6)
Parity
Nulliparity 12 039 (54.0) 11 996 (54.0) 7 (53.8) 36 (56.3) 0.957
Multiparity 10 244 (46.0) 10 210 (46.0) 6 (46.2) 28 (43.8)
Family history of hypertension
No 21 337 (95.8) 21 261 (95.7) 13 (100.0) 63 (98.4) 0.731b
Yes 946 (4.2) 945 (4.3) 0 (0.0) 1 (1.6)
Family history of diabetes
No 21 871 (98.2) 21 795 (98.1) 13 (100.0) 63 (98.4) 1.000 b
Yes 412 (1.8) 411 (1.9) 0 (0.0) 1 (1.6)

Table 2

Trend of serum vitamin E concentrations by year of delivery in first trimester of pregnancy among the participants from January 2016 through December 2018"

Year of delivery n Median (P25- P75)/
(mg/L)a		 Number of women in different serum vitamin E concentration levels, n (%)
< P20 P20- P40 P40- P60 P60- P80 > P80 Pb
2016 7 216 9.7 (8.5-11.2) 1 776 (24.6) 1 573 (21.8) 1 392 (19.3) 1 313 (18.2) 1 162 (16.1) <0.001
2017 7 677 10.2 (9.0-11.8) 1 269 (16.5) 1 500 (19.5) 1 522 (19.8) 1 618 (21.1) 1 768 (23.0)
2018 7 390 10.3 (8.9-11.8) 1 319 (17.8) 1 406 (19.0) 1 383 (18.7) 1 541 (20.9) 1 741 (23.6)
Total 22 283 10.1 (8.8-11.6) 4 364 (19.6) 4 479 (20.1) 4 297 (19.3) 4 472 (20.1) 4 671 (21.0)

Table 3

The incidences of HDCP among participants from January 2016 through December 2018 [n (%)]"

Year of delivery n HDCP Gestational hypertension Mild preeclampsia Severe preeclampsia Eclampsia
2016 7 216 345 (4.8) 150 (2.1) 95 (1.3) 100 (1.4) 0 (0.0)
2017 7 677 428 (5.6) 147 (1.9) 152 (2.0) 126 (1.6) 3 (< 0.1)
2018 7 390 432 (5.8) 179 (2.4) 115 (1.6) 136 (1.8) 2 (< 0.1)
Total 22 283 1 205 (5.4) 476 (2.1) 362 (1.6) 362 (1.6) 5 (< 0.1)
χtrend2a - 8.058 2.286 1.420 5.435b
P - 0.005 0.131 0.233 0.020

Table 4

The incidences of HDCP among participants by their vitamin E nutritional status [n (%)]"

VE nutritional statusa n HDCP Gestational hypertension Mild preeclampsia Severe preeclampsia Eclampsia
Normal 22 206 1 197 (5.4) 472 (2.1) 359 (1.6) 361 (1.6) 5 (< 0.1)
Deficient 13 1 (7.7) 1 (7.7) 0 (0.0) 0 (0.0) 0 (0.0)
Excessive 64 7 (10.9) 3 (4.7) 3 (4.7) 1 (1.6) 0 (0.0)
Total 22 283 1 205 (5.4) 476 (2.1) 362 (1.6) 362 (1.6) 5 (< 0.1)

Table 5

Association between serum vitamin E concentrations in first trimester of pregnancy and the risks of HDCP"

Outcome VE concentration
levels /(mg/L)		 n Incidences,
n (%)		 Crude
OR (95%CI)		 P Adjusted
OR (95%CI)a		 P
HDCP
8.8 - 11.6 11 360 567 (5.0) 1.00 1.00
< 8.8 5 442 250 (4.6) 0.92 (0.79 - 1.07) 0.263 0.98 (0.84 - 1.14) 0.766
> 11.6 5 481 388 (7.1) 1.45 (1.27 - 1.66) <0.001 1.34 (1.17 - 1.53) <0.001
Gestational hypertension
8.8 - 11.6 11 008 215 (2.0) 1.00 1.00
< 8.8 5 303 111 (2.1) 1.07 (0.85 - 1.35) 0.550 1.13 (0.89 - 1.42) 0.321
> 11.6 5 243 150 (2.9) 1.48 (1.20 - 1.83) <0.001 1.39 (1.13 - 1.72) 0.002
Preeclampsia-eclampsia
8.8 - 11.6 11 145 352 (3.2) 1.00 1.00
< 8.8 5 331 139 (2.6) 0.82 (0.67 - 1.00) 0.052 0.88 (0.72 - 1.07) 0.206
> 11.6 5 331 238 (4.5) 1.43 (1.21 - 1.70) <0.001 1.34 (1.13 - 1.59) 0.001

Table 6

Variation of pre-pregnant body mass index of the participants by years of delivery [n(%)]"

Year of delivery n Underweight Normal Overweight Obesity Pa
2016 7 216 790 (10.9) 4 596 (63.7) 1 353 (18.8) 477 (6.6) 0.651
2017 7 677 786 (10.2) 4 788 (62.4) 1 644 (21.4) 459 (6.0)
2018 7 390 764 (10.3) 4 695 (63.5) 1 504 (20.4) 427 (5.8)
Total 22 283 2 340 (10.5) 14 079 (63.2) 4 501 (20.2) 1 363 (6.1)

Table 7

The relationships between pre-pregnant BMI and incidence of HDCP or serum vitamin E concentration levels in the women at first trimester of pregnancy"

Pre-pregnant BMI n HDCP VE concentration/(mg/L)
Incidence (n, %)a AOR (95%CI)b Median (P25 - P75) Pc Pd Pe
Underweight 2 340 62 (2.6) 0.64 (0.49 - 0.83) 9.8 (8.5 - 11.2) <0.001 <0.001 -
Normal 14 079 568 (4.0) 1.00 10.0 (8.7 - 11.5) - -
Overweight 4 501 374 (8.3) 2.15 (1.87 - 2.47) 10.4 (9.1 - 12.0) <0.001 0.723
Obesity 1 363 201 (14.7) 4.12 (3.46 - 4.91) 10.5 (9.1 - 12.2) <0.001
All participants 22 283 1 205 (5.4) - 10.1 (8.8 - 11.6) - -

Figure 2

The crude odds ratios (95%CI) for incidences of HDCP at different serum vitamin E concentration levels in women in first trimester of pregnancy (n = 22 283) COR, crude odds ratio; CI, confidence interval; VE, vitamin E."

Figure 3

The adjusted odds ratios (95%CI) for incidences of HDCP at different serum vitamin E concentration levels in women in first trimester of pregnancy (n = 22 283) The potential confounders in the multivariable Logistic regression models were: year of delivery; maternal age; education level; parity; pre-pregnant BMI; family history of hypertension; family history of diabetes. AOR, adjusted odds ratio; CI, confidence interval."

[1] 谢幸, 苟文丽. 妇产科学[M]. 8版. 北京: 人民卫生出版社, 2013: 42, 64.
[2] 中华医学会妇产科学分会妊娠期高血压疾病学组. 妊娠期高血压疾病诊治指南(2015)[J]. 中华围产医学杂志, 2016,19(3):161-169.
[3] Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis[J]. Hypertens Res, 2017,40(3):213-220.
pmid: 27682655
[4] Ye C, Ruan Y, Zou L, et al. The 2011 survey on hypertensive disorders of pregnancy (HDP) in China: prevalence, risk factors, complications, pregnancy and perinatal outcomes[J]. PLoS One, 2014,9(6):e100180.
[5] You SH, Cheng PJ, Chung TT, et al. Population-based trends and risk factors of early- and late-onset preeclampsia in Taiwan 2001—2014[J]. BMC Pregnancy Childbirth, 2018,18(1):199.
pmid: 29855344
[6] Paré E, Parry S, McElrath TF, et al. Clinical risk factors for preeclampsia in the 21st century[J]. Obstet Gynecol, 2014,124(4):763-770.
[7] Redman CW, Sargent IL. Latest advances in understanding preeclampsia[J]. Science, 2005,308(5728):1592-1594.
pmid: 15947178
[8] 殷为, 钟梅. 妊娠期高血压疾病的病因、预测及诊疗进展[J]. 实用医学杂志, 2016,32(11):1887-1890.
[9] 孙长颢. 营养与食品卫生学[M]. 8版. 北京: 人民卫生出版社, 2017: 93-95, 215.
[10] 郭方, 李笑天. 叶酸及多种维生素的补充对妊娠期高血压疾病的预防作用[J]. 中国实用妇科与产科杂志, 2014,30(8):592-596.
[11] Rumbold A, Ota E, Hori H, et al. Vitamin E supplementation in pregnancy[J]. Cochrane Database Syst Rev, 2015(9): CD004069.
[12] Zhang C, Williams MA, Sanchez SE, et al. Plasma concentrations of carotenoids, retinol, and tocopherols in preeclamptic and normotensive pregnant women[J]. Am J Epidemiol, 2001,153(6):572-580.
pmid: 11257065
[13] Roberts JM, Myatt L, Spong CY, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension[J]. N Engl J Med, 2010,362(14):1282-1291.
[14] Poston L, Briley AL, Seed PT, et al. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial[J]. Lancet, 2006,367(9517):1145-1154.
[15] Rajasingam D, Seed PT, Briley AL, et al. A prospective study of pregnancy outcome and biomarkers of oxidative stress in nulliparous obese women[J]. Am J Obstet Gynecol, 2009,200(4):395.
pmid: 19200933
[16] 康忠春, 陈远兰, 邹余粮. 妊娠子痫前期孕妇维生素A、E水平及其影响因素分析[J]. 临床医学研究与实践, 2018,3(30):142-144.
[17] 张翠, 靳颖, 杨洁, 等. 河北省产妇2016年妊娠期高血压疾病患病情况分析[J]. 中国公共卫生, 2018,34(10):1395-1397.
[18] 牛影, 徐叶清, 郝加虎, 等. 马鞍山市妇女孕前体质指数和孕期增重与妊娠期高血压疾病的队列研究[J]. 卫生研究, 2016,45(2):205-210.
[19] 申南, 陆娣, 郑春梅, 等. 常规保健下不同年龄段孕妇妊娠早期血清维生素A、E水平分析[J]. 中国妇产科临床杂志, 2018,19(4):356-358.
[20] 闫明, 张雯, 刘凯波, 等. 北京地区2010年—2017年增补叶酸预防神经管缺陷工作效果分析[J]. 中国优生与遗传杂志, 2019,27(3):339-341.
[21] Schiff E, Friedman SA, Stampfer M, et al. Dietary consumption and plasma concentrations of vitamin E in pregnancies complicated by preeclampsia[J]. Am J Obstet Gynecol, 1996,175(4 Pt 1):1024-1028.
[22] Bartsch E, Medcalf KE, Park AL, et al. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies[J]. BMJ, 2016,353:i1753.
pmid: 27094586
[23] Rumbold AR, Crowther CA, Haslam RR, et al. Vitamins C and E and the risks of preeclampsia and perinatal complications[J]. N Engl J Med, 2006,354(17):1796-1806.
[24] Bowman BA, Russell RM. 现代营养学[M]. 8版. 荫士安,汪之顼, 译. 北京: 化学工业出版社, 2004: 195.
[25] Karpińska J, Mikołuć B, Motkowski R, et al. HPLC method for simultaneous determination of retinol, alpha-tocopherol and coenzyme Q10 in human plasma [J]. J Pharm Biomed Anal, 2006,42(2):232-236.
[26] 马蕊, 刘建蒙, 李松, 等. 浙江省嘉兴地区妊娠高血压综合征发病状况研究[J]. 中华流行病学杂志, 2005,26(12):960-963.
[27] Yusuf H, Subih HS, Obeidat BS, et al. Associations of macro and micronutrients and antioxidants intakes with preeclampsia: A case-control study in Jordanian pregnant women[J]. Nutr Metab Car-diovasc Dis, 2019,29(5):458-466.
[28] 孟凡文, 陈森, 刘亚山, 等. 河北省5县区妊娠期高血压疾病的发病情况及危险因素分析[J]. 中国生育健康杂志, 2015,26(2):112-115.
[1] Xinyi LI, Jinxia ZHAO, Rong MU. Impact of aspirin use on pregnancy outcomes in patients with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1074-1080.
[2] Mengxi LU, Qiuping LIU, Tianjing ZHOU, Xiaofei LIU, Yexiang SUN, Peng SHEN, Hongbo LIN, Xun TANG, Pei GAO. Association of triglyceride-glucose index and cardiovascular disease in a community-based Chinese cohort [J]. Journal of Peking University (Health Sciences), 2025, 57(3): 430-435.
[3] Shuhan YANG, Yixin LI, Haoliang CUI, Youxin WANG, Yuying WU, Mingyue WANG, Yifan YANG, Nur Enkar, Lei YANG, Hui WANG. Associations of metabolic dysfunction-associated steatotic liver disease and cardiometabolic risk factor abnormalities with adverse pregnancy outcomes [J]. Journal of Peking University (Health Sciences), 2025, 57(3): 487-495.
[4] Wen BIAN, Wenjun ZHOU, Tianchen WU, Peijing ZHU, Yinuo CHEN, Pengbo YUAN, Xueju WANG, Ying WANG, Yuan WEI, Yangyu ZHAO. Perinatal outcomes of single intrauterine fetal demise in monochorionic diamniotic twins [J]. Journal of Peking University (Health Sciences), 2025, 57(3): 592-598.
[5] Wenqiong WANG, Yuke HOU, Chun LI, Xuewu ZHANG. Predictors of adverse pregnancy outcomes in patients with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2025, 57(3): 599-603.
[6] Junjuan YANG, Lei ZHANG, Yan ZHANG. Pregnancy complicated by patent urachus: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 393-395.
[7] Fangfei XIE, Hong QIAO, Boya LI, Cui YUAN, Fang WANG, Yu SUN, Shuangling LI. Severe malnutrition during pregnancy complicated with acute pyelonephritis causing sepsis, refractory septic shock and multiple organ failure: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(1): 202-207.
[8] Mingxia WANG, Ling DING, Min WANG, Chanjuan ZOU, Siyu YAN, Yingwen LIANG, Weijia WANG, Shanzhi HE. Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1119-1125.
[9] Huichao MA,Jun LI,Yongqing WANG. Clinical characteristics of pregnancy complicated with inflammatory bowel disease [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 260-266.
[10] Yangyang LI,Lin HOU,Zijun MA,Shanyamei HUANG,Jie LIU,Chaomei ZENG,Jiong QIN. Association of pregnancy factors with cow's milk protein allergy in infants [J]. Journal of Peking University (Health Sciences), 2024, 56(1): 144-149.
[11] Fang-ning YOU,Liang LUO,Xiang-jun LIU,Xue-wu ZHANG,Chun LI. Analysis of pregnancy outcomes, disease progression, and risk factors in patients with undifferentiated connective tissue disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1045-1052.
[12] Yu-fei LI,Ya-ni YAN,Jia-yang JIN,Chun LI,Qiu-yan PEI. Clinical characteristics of fetal cardiac disease in patients with anti-SSA antibody positive [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1053-1057.
[13] Chu-yun CHEN,Peng-fei SUN,Jing ZHAO,Jia JIA,Fang-fang FAN,Chun-yan WANG,Jian-ping LI,Yi-meng JIANG,Yong HUO,Yan ZHANG. Related factors of endogenous erythropoietin and its association with 10-year risks of cardiovascular disease in a community-based Chinese study [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1068-1073.
[14] Jie WU,Wen ZHANG,Shu LIANG,Yi-lu QIN,Wen-qiang FAN. Pregnancy-associated neuromyelitis optical spectrum disorder combined with primary Sjögren's syndrome: A critical illness case report [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1118-1124.
[15] Jin-hui XU,Na HAN,Tao SU,Li-zi LIN,Yue-long JI,Shuang ZHOU,He-ling BAO,Zheng LIU,Shu-sheng LUO,Xiang-rong XU,Hai-jun WANG. Association of maternal isolated thyroid peroxidase antibody positive in the first trimester with fetal growth [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 886-892.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd